New drug shows promise for rare stomach disease
NCT ID NCT03678545
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested dupilumab, a drug that calms certain immune reactions, in 41 people aged 12-70 with eosinophilic gastritis, a condition where too many immune cells build up in the stomach lining. Participants received either dupilumab or a placebo injection every two weeks for 12 weeks. The main goal was to see if the drug reduced stomach inflammation compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dupilumab (a drug that blocks certain immune signals to reduce inflammation)
What this could lead to
If it works, this could point toward a treatment for eosinophilic gastritis, a rare stomach condition causing pain and swelling.
What could go wrong
This is a small, early-phase trial with only 41 people. The drug may not reduce stomach inflammation better than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GASTROENTERITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Northwestern Medicine Digestive Health Center
Chicago, Illinois, 60611, United States
-
Riley Children's Hospital
Indianapolis, Indiana, 46202, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
University of Colorado Denver and Hospital
Aurora, Colorado, 80045, United States
-
University of North Carolina School of Medicine
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Utah Hospital
Salt Lake City, Utah, 84132, United States